Bath Savings Trust Co Boosts Holdings in Pfizer Inc. (NYSE:PFE)

Bath Savings Trust Co grew its stake in shares of Pfizer Inc. (NYSE:PFE) by 10.1% during the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 45,820 shares of the biopharmaceutical company’s stock after buying an additional 4,205 shares during the period. Bath Savings Trust Co’s holdings in Pfizer were worth $1,272,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. GoalVest Advisory LLC grew its holdings in Pfizer by 304.9% in the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 811 shares during the last quarter. Creekmur Asset Management LLC bought a new stake in shares of Pfizer during the 4th quarter valued at about $32,000. VisionPoint Advisory Group LLC boosted its stake in shares of Pfizer by 52,350.0% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 1,047 shares in the last quarter. Tennessee Valley Asset Management Partners bought a new stake in shares of Pfizer during the 4th quarter valued at about $36,000. Finally, DiNuzzo Private Wealth Inc. purchased a new position in Pfizer during the 4th quarter valued at about $37,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on PFE shares. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research report on Monday. Morgan Stanley lifted their price target on shares of Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a research report on Thursday, May 2nd. Guggenheim initiated coverage on shares of Pfizer in a report on Friday, February 23rd. They issued a “buy” rating and a $36.00 target price for the company. Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Finally, BMO Capital Markets reaffirmed an “outperform” rating and issued a $36.00 target price (up from $33.00) on shares of Pfizer in a report on Thursday, May 2nd. Ten analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $35.86.

Pfizer Stock Performance

PFE opened at $27.41 on Thursday. The firm has a market cap of $155.32 billion, a P/E ratio of -456.76, a PEG ratio of 1.08 and a beta of 0.70. Pfizer Inc. has a 1-year low of $25.20 and a 1-year high of $39.87. The company has a 50 day simple moving average of $27.61 and a two-hundred day simple moving average of $27.73. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.05 and a quick ratio of 0.78.

Pfizer (NYSE:PFE) last released its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 EPS for the quarter, topping the consensus estimate of $0.56 by $0.26. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The firm had revenue of $14.88 billion for the quarter, compared to the consensus estimate of $13.87 billion. During the same quarter in the previous year, the firm earned $1.23 earnings per share. The company’s quarterly revenue was down 19.5% compared to the same quarter last year. Equities analysts forecast that Pfizer Inc. will post 2.38 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, June 14th. Investors of record on Friday, May 10th were paid a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a yield of 6.13%. The ex-dividend date was Thursday, May 9th. Pfizer’s payout ratio is -2,799.53%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.